AstraZeneca: after Ema's yes, we are ready to provide the vaccine in 24 hours
Coronavirus.
Oxford-AstraZeneca vaccine, 90% efficacy with half dose
Irbm Pomezia: AstraZeneca vaccine data for approval in 7 days
Share
27 December 2020The British pharmaceutical group AstraZeneca assures that it has found the "winning formula" to ensure that its vaccine against Covid-19, which it has worked on together at the University of Oxford and which also collaborates with an Italian company, has an effectiveness equal to those of Pfizer / BioNTech, 95% and Moderna, 94%.
"We believe we have found the winning formula to obtain an efficacy that, after two doses, is equal to all the others", explained the CEO, Pascal Soriot, to the Sunday Times.
Soriot declined to provide further details, pending the results of the new studies.
But according to the British press, the 'green light' of the British regulators for the British vaccine is now a matter of days.
The Oxford / AstraZeneca vaccine is eagerly awaited because it is relatively inexpensive (four dollars a dose) and can be stored in conventional and non-70 degree freezers like Pfizer / BioNTech's;
which facilitates vaccination on a large scale and in nursing homes.
In November, AstraZeneca and Oxford had published the preliminary results of their clinical study in two groups: one received two full doses of the vaccine, resulting in a 62% efficacy result, while the other received half a dose, followed by one dose. completed the following month, and that was exactly 90% effective.
The results were also heavily criticized because the half-dose injection was due to an error and this protocol was followed by a relatively small group of people;
for this the company announced that the vaccine required "further studies".